A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients with Advanced Malignancies Harboring MEK or Atypical BRAF Alterations
Study of Ulixertinib (BVD-523) for Patients with Advanced Cancer that Show Genetic Alterations
Sponsor: BioMed Valley Discoveries, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAT6805
U.S. Govt. ID: NCT04488003
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to assess the safety and tolerability of an experimental study drug called ulixertinib (BVD-523) in the treatment of advanced cancer that shows certain genetic alterations (changes in the DNA) called MEK or atypical BRAF alterations and is getting worse. Experimental means that ulixertinib has not received authorization to be marketed for use within the USA. Ulixertinib works by inhibiting (blocking) tumor cells ' EKR1/2 pathways, which can cause the tumor to stop growing or spreading. Cancers include bladder cancer, colon and rectal cancer, head and neck, kidney cancer, liver cancer, lung cancer, pancreatic cancer, and prostate cancer.
Investigator
Richard Carvajal, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Do you have advanced cancer that has genetic mutations? Yes No
Has your cancer gotten worse while taking prior therapy? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162